[
  {
    "ts": "2025-08-06T16:23:20+00:00",
    "headline": "Vertex Pharmaceuticals (VRTX) Hits New All-Time Low on Failed Clinical Trial",
    "summary": "We recently published 10 Big Names Bleed Double Digits. Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) is one of the worst-performing stocks on Tuesday. Vertex Pharmaceuticals nosedived on Tuesday to hit a new all-time low following the termination of a clinical trial for an experimental pain medicine. The company dropped as low as 21 percent to $373.2 before […]",
    "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-hits-time-162320805.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "c97f0158-8fb2-3a87-85ac-0f8cbe3d3dc0",
      "content": {
        "id": "c97f0158-8fb2-3a87-85ac-0f8cbe3d3dc0",
        "contentType": "STORY",
        "title": "Vertex Pharmaceuticals (VRTX) Hits New All-Time Low on Failed Clinical Trial",
        "description": "",
        "summary": "We recently published 10 Big Names Bleed Double Digits. Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) is one of the worst-performing stocks on Tuesday. Vertex Pharmaceuticals nosedived on Tuesday to hit a new all-time low following the termination of a clinical trial for an experimental pain medicine. The company dropped as low as 21 percent to $373.2 before […]",
        "pubDate": "2025-08-06T16:23:20Z",
        "displayTime": "2025-08-06T16:23:20Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/cb218414709808bf2f63f98ca522d436",
          "originalWidth": 1280,
          "originalHeight": 853,
          "caption": "Vertex Pharmaceuticals (VRTX) Hits New All-Time Low on Failed Clinical Trial",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tXp3W2zDkWcbYHYM_edP3Q--~B/aD04NTM7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/cb218414709808bf2f63f98ca522d436.cf.webp",
              "width": 1280,
              "height": 853,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BuRra1_S02PEU8kqjSl2RA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/cb218414709808bf2f63f98ca522d436.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-hits-time-162320805.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-hits-time-162320805.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-06T13:36:40+00:00",
    "headline": "Snap downgraded, Leidos upgraded: Wall Street's top analyst calls",
    "summary": "Snap downgraded, Leidos upgraded: Wall Street's top analyst calls",
    "url": "https://finance.yahoo.com/news/snap-downgraded-leidos-upgraded-wall-133640590.html",
    "source": "The Fly",
    "provider": "yfinance",
    "raw": {
      "id": "56d775ec-ed9a-3792-bb29-64101908a6b6",
      "content": {
        "id": "56d775ec-ed9a-3792-bb29-64101908a6b6",
        "contentType": "STORY",
        "title": "Snap downgraded, Leidos upgraded: Wall Street's top analyst calls",
        "description": "",
        "summary": "Snap downgraded, Leidos upgraded: Wall Street's top analyst calls",
        "pubDate": "2025-08-06T13:36:40Z",
        "displayTime": "2025-08-06T13:36:40Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/the_fly_169/5039a5ccc6ec98e1b92bc672330bfcec",
          "originalWidth": 1200,
          "originalHeight": 628,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YHTvjvqtNAYBPYViMXYCow--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/the_fly_169/5039a5ccc6ec98e1b92bc672330bfcec.cf.webp",
              "width": 1200,
              "height": 628,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/J3gfZRz3Jb2im4_aLYVn4g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/the_fly_169/5039a5ccc6ec98e1b92bc672330bfcec.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Fly",
          "url": "https://thefly.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/snap-downgraded-leidos-upgraded-wall-133640590.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/snap-downgraded-leidos-upgraded-wall-133640590.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MNDY"
            },
            {
              "symbol": "CACI"
            },
            {
              "symbol": "SEAT"
            },
            {
              "symbol": "SEATW"
            },
            {
              "symbol": "BRBR"
            },
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "INDV"
            },
            {
              "symbol": "PVLA"
            },
            {
              "symbol": "IT"
            },
            {
              "symbol": "XLO"
            },
            {
              "symbol": "KMPR"
            },
            {
              "symbol": "ALC"
            },
            {
              "symbol": "FOUR"
            },
            {
              "symbol": "FOUR-PA"
            },
            {
              "symbol": "LDOS"
            },
            {
              "symbol": "SNAP"
            },
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-06T10:47:14+00:00",
    "headline": "Vertex Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations",
    "summary": "NasdaqGS:VRTX 1 Year Share Price vs Fair Value Explore Vertex Pharmaceuticals's Fair Values from the Community and...",
    "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-second-quarter-2025-104714593.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "6e903ce4-86f6-3cb7-a4de-3962629551a7",
      "content": {
        "id": "6e903ce4-86f6-3cb7-a4de-3962629551a7",
        "contentType": "STORY",
        "title": "Vertex Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations",
        "description": "",
        "summary": "NasdaqGS:VRTX 1 Year Share Price vs Fair Value Explore Vertex Pharmaceuticals's Fair Values from the Community and...",
        "pubDate": "2025-08-06T10:47:14Z",
        "displayTime": "2025-08-06T10:47:14Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c",
          "originalWidth": 945,
          "originalHeight": 636,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uJL6bHu6ZvrkfEMEXrej0w--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c.cf.webp",
              "width": 945,
              "height": 636,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6q7m4tTcuA7S9BaxIiz0Jw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-second-quarter-2025-104714593.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-second-quarter-2025-104714593.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-06T10:10:12+00:00",
    "headline": "S&P Futures Gain With Focus on Earnings and Fed Speak",
    "summary": "September S&P 500 E-Mini futures (ESU25) are trending up +0.24% this morning as investors digested U.S. President Donald Trump’s latest tariff threats and weak economic data, with the focus now shifting to a fresh batch of corporate earnings reports and remarks from Federal Reserve officials.",
    "url": "https://www.barchart.com/story/news/33915377/s-p-futures-gain-with-focus-on-earnings-and-fed-speak",
    "source": "Barchart",
    "provider": "yfinance",
    "raw": {
      "id": "98f486e7-111e-3270-baf6-44658935103a",
      "content": {
        "id": "98f486e7-111e-3270-baf6-44658935103a",
        "contentType": "STORY",
        "title": "S&P Futures Gain With Focus on Earnings and Fed Speak",
        "description": "",
        "summary": "September S&P 500 E-Mini futures (ESU25) are trending up +0.24% this morning as investors digested U.S. President Donald Trump’s latest tariff threats and weak economic data, with the focus now shifting to a fresh batch of corporate earnings reports and remarks from Federal Reserve officials.",
        "pubDate": "2025-08-06T10:10:12Z",
        "displayTime": "2025-08-06T10:10:12Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/barchart_com_477/a7ae4b2672b6ce658bd7fe96a66c5b12",
          "originalWidth": 1600,
          "originalHeight": 1155,
          "caption": "New York Stock Exchange during sunrise by Deberarr via iStock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cUOr0_lwffTfrJheO25KQA--~B/aD0xMTU1O3c9MTYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/barchart_com_477/a7ae4b2672b6ce658bd7fe96a66c5b12.cf.webp",
              "width": 1600,
              "height": 1155,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kWSxDqJtRccrETVJ3bAZSg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/barchart_com_477/a7ae4b2672b6ce658bd7fe96a66c5b12.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barchart",
          "url": "https://www.barchart.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barchart.com/story/news/33915377/s-p-futures-gain-with-focus-on-earnings-and-fed-speak",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/p-futures-gain-focus-earnings-101012499.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "^SPX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-06T09:36:03+00:00",
    "headline": "Vertex’s Journavx successor culled in acute pain after falling short in Phase II",
    "summary": "Topline results reveal that VX-993 did not meet its primary endpoints, meaning Vertex will discontinue its development in acute pain.",
    "url": "https://www.clinicaltrialsarena.com/news/vertex-pharmaceuticals-phase-ii-pain-trial-results/",
    "source": "Clinical Trials Arena",
    "provider": "yfinance",
    "raw": {
      "id": "7852a1c9-9c48-3af1-a78f-c92eb974df9b",
      "content": {
        "id": "7852a1c9-9c48-3af1-a78f-c92eb974df9b",
        "contentType": "STORY",
        "title": "Vertex’s Journavx successor culled in acute pain after falling short in Phase II",
        "description": "",
        "summary": "Topline results reveal that VX-993 did not meet its primary endpoints, meaning Vertex will discontinue its development in acute pain.",
        "pubDate": "2025-08-06T09:36:03Z",
        "displayTime": "2025-08-06T09:36:03Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/clinical_trials_arena_396/77931414bf154bac8f7e3d996a0a7e11",
          "originalWidth": 2120,
          "originalHeight": 1414,
          "caption": "Vertex Pharmaceuticals' Journavx successor",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4xVsf_cUZG1NnSUWKjo4Ag--~B/aD0xNDE0O3c9MjEyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/clinical_trials_arena_396/77931414bf154bac8f7e3d996a0a7e11.cf.webp",
              "width": 2120,
              "height": 1414,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CLuAj9PdmmR5BK9EubAcnQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/clinical_trials_arena_396/77931414bf154bac8f7e3d996a0a7e11.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Clinical Trials Arena",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.clinicaltrialsarena.com/news/vertex-pharmaceuticals-phase-ii-pain-trial-results/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-journavx-successor-culled-falling-093603964.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-06T08:42:00+00:00",
    "headline": "7 Reasons Why Vertex Pharmaceuticals Is a No-Brainer Stock to Buy on the Dip",
    "summary": "There's more good news than bad news for this big biotech stock.",
    "url": "https://www.fool.com/investing/2025/08/06/7-reasons-why-vertex-pharmaceuticals-is-a-no-brain/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "a37136aa-e2cc-39d8-b981-13333df1c5a0",
      "content": {
        "id": "a37136aa-e2cc-39d8-b981-13333df1c5a0",
        "contentType": "STORY",
        "title": "7 Reasons Why Vertex Pharmaceuticals Is a No-Brainer Stock to Buy on the Dip",
        "description": "",
        "summary": "There's more good news than bad news for this big biotech stock.",
        "pubDate": "2025-08-06T08:42:00Z",
        "displayTime": "2025-08-06T08:42:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/9b4a18c492e27abb7c6849eec0d466a6",
          "originalWidth": 1400,
          "originalHeight": 817,
          "caption": "A scientist looking through a microscope.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QdcH5Fq7i4Aj.iag9EYMJg--~B/aD04MTc7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/9b4a18c492e27abb7c6849eec0d466a6.cf.webp",
              "width": 1400,
              "height": 817,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Z57A3ZrGXuzIMNbneZOltw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/9b4a18c492e27abb7c6849eec0d466a6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/08/06/7-reasons-why-vertex-pharmaceuticals-is-a-no-brain/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/7-reasons-why-vertex-pharmaceuticals-084200147.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]